From Second Sight’s South Korean market entry to Sanuwave’s Indonesian distribution deal, here are medtech stories we missed this week but thought were still worth mentioning. 1. Second Sight enters South Korea market Second Sight announced in a July 5 press release that it has entered the market in South Korea with the implantation of two […]
Diagnostics
Epilepsy biomarker could aid in early detection, targeted treatment
Researchers from the University of Illinois at Chicago College of Medicine have identified a unique chemical biomarker associated with epileptic brain tissue, according to an article published in the journal Epilepsia. The chemical signature can be detected noninvasively and could enable physicians to precisely locate small regions of abnormal brain tissue in early-stage patients. The researchers […]
OpGen prices $10m public offering
OpGen (NSDQ:OPGN) said earlier this month that it priced a $10 million public offering of 25 million units of common stock and warrants at 40¢ apiece. The molecular diagnostics company said each common warrant has an exercise price of 43¢ per share and expires five years after issuance. The offering is slated to close tomorrow. […]
Mobile diagnostic device detects tumor cells in blood
Researchers from the Rovira i Virgili University have developed and patented a mobile diagnostic device that can detect tumor cells in blood, according to a study published in Scientific Reports. The team reported that the device can quantify tumor cells in a blood sample in real-time, positioning it as a tool to boost the diagnosis and […]
Abbott launches tender offer for Alere in $5.3B merger
Abbott (NYSE:ABT) said today that it launched the tender offer for its $5.3 billion acquisition of diagnostics giant Alere (NYSE:ALR). The $402-per-share tender offer is slated to expire at midnight on August 11, Abbott said. The merger was amended in April, when Abbott agreed to pay $5.3 billion for Alere rather than the original price […]
Trovagene raises $7m for precision cancer therapies
Trovagene (NSDQ:TROV) said today that it inked a deal with unnamed investors to sell approximately $7.1 million of its common stock. According to the deal, Trovagene plans to sell 6,191,500 shares of common stock. In a concurrent private placement, the biotech said it will issue warrants to buy up to 4,643,626 shares of common stock. […]
Medtech stories we missed this week: July 14, 2017
From Novarad touting its VR-surgical guidance system to Zynex paying off its $2.2M loan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Stimwave announces first patient in Brazil Stimwave announced in a July 5 press release that its first patients in Brazil have received Stimwave’s wireless pain relief […]
Blood test enhances early detection of pancreatic cancer
Researchers from the University of Pennsylvania have devised a biomarker panel that could enable earlier diagnosis and better treatment for patients with pancreatic cancer, according to a study published in Science Translational Medicine. Pancreatic cancer is the fourth leading cause of cancer death in the U.S., the team reported, and often patients are not diagnosed until […]
Rennova to spin off advanced molecular services biz
Rennova Health (NSDQ:RNVA) said today that it plans to spin off its advanced molecular services division into an independent, publicly-traded company. The spin-off is slated to take place at the end of September. Rennova’s board has also cleared the spin-off of its health technology solutions arm in a similar deal, according to the company. “We […]
‘Nanolock’ could help diagnose and treat cancer with individualized therapies
In a study published in ACS Sensors, a team of researchers described how they develop a method to recognize a particular mutation in the genetic code of a cancerous cell. If cancers are caught early enough in the cell mutation process, many of them can be stopped with chemotherapy and other forms of treatment. This new […]